Pasar al contenido principal

PRUEBA CLÍNICA DE CONCEPTO DE UN PRIMER INHIBIDOR DE MYC EN SU CLASE EN TERAPIA DE COMBINACIÓN Y EXPANSIÓN DE SU PLAN DE DESARROLLO

CPP2022-009808

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Transferencia de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario PEPTOMYC SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  • Giuntini, Fabio
  • Massó-Vallés, Daniel
  • Whitfield, Jonathan
  • Soucek, Laura
DNA damage response; DNA damage response inhibitors; MYC inhibition, Respuesta al daño del ADN; Inhibidores de la respuesta al daño del ADN; Inhibición de MYC, Resposta al dany de l'ADN; Inhibidors de la resposta al dany de l'ADN; Inhibició de MYC, MYC performs a dual role in DNA Damage Response (DDR), promoting genomic instability through replication stress, R-loop formation, and topoisomerase-mediated damage, while simultaneously activating DNA repair pathways to maintain cell survival. This review provides a comprehensive analysis of how MYC inhibition affects DDR pathway dependencies. In fact, when MYC is inhibited, cancer cells lose both their proficient DNA repair capacity and their protective mechanisms against replication stress. This creates a therapeutic window in which combining MYC inhibitors with DDR-targeting agents may achieve synergistic anti-cancer effects. Central to this approach is the exploration of rational combination strategies that pair MYC inhibitors with various DDR modulators including Poly (ADP-ribose) polymerase (PARP) inhibitors, ATR/CHK1 inhibitors, and other DNA repair pathway disruptors. This review summarizes preclinical evidence demonstrating enhanced therapeutic efficacy when MYC inhibition is combined with DDR-targeting agents and discusses early clinical findings that support this promising therapeutic strategy., The author(s) declared that financial support was received for this work and/or its publication. We thank the Spanish Association of Metastatic Breast Cancer for the Chiara Giorgetti Award 2022, Instituto de Salud Carlos III (FI20/00274 – FG PFIS doctoral bursary), Ministerio de Ciencia e Innovación (Retos de Colaboración RTC2019-007067-1, Líneas Estratégicas PLEC2021-007959), Generalitat de Catalunya (AGAUR 2017/SGR 537 and 2021/SGR 01509), EDIReX (H2020 INFRAIA 731105-2), the European Research Council (ERC-2023-ADG 101142260), the Spanish Ministry of Science and Innovation and European Union through the NextGenerationEU program, in the context of the Plan de Recuperacion, Transformacion y Resiliencia (RETOS; CPP2022-009808) and the FERO foundation for funding support.